Stock AnalizTransMedics Group, Inc. TMDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2019 · data as of November 13, 2026
TransMedics Group, Inc. (TMDX) is a healthcare company listed in the US with a market value of about $3.2B. In the twelve months to September 30, 2026 it had revenue of $728M and net income of $144M, a net margin of 19.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 25.0, a price to free cash flow of 71.0, 5-year revenue growth of 84% a year, a 5-year average ROIC of -6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 66% below the current price.
Score: 2.0 / 5
Checks passed
- P/E below 25
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- Positive free cash flow
Checks not passed
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $728M | $605M | $442M | $242M | $93M | $31M | $28M | $26M | $15M |
| Net income | $144M | $190M | $35M | -$25M | -$36M | -$44M | -$29M | -$34M | -$24M |
| Free cash flow | $45M | $134M | -$81M | -$165M | -$58M | -$32M | -$31M | -$32M | -$26M |
| EPS (diluted) | $3.66 | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | $-2.36 | $-17.48 |
| Net margin | 19.9% | 31.4% | 8.0% | -10.4% | -38.8% | -140.9% | -101.4% | -129.8% | -162.1% |
| ROIC | — | 9.1% | 5.4% | -4.5% | -9.7% | -27.9% | -19.0% | -33.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $104.55, 14% above the current price; targets range from $70.00 to $125.00; the consensus rating is “Buy”; expected EPS is $1.67 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is TransMedics Group’s P/E ratio?
About 25.0, based on the last twelve months of diluted earnings per share (forward P/E about 42.3).
Is TransMedics Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 66% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does TransMedics Group pay a dividend?
Not currently.
Is TransMedics Group a good stock to buy?
We do not give buy or sell advice. TransMedics Group scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.